Welcome to Gedeon Richter PregLem
Developing first-in-class therapies for gynaecologic conditions with significant unmet needsLearn more
Gedeon Richter PregLem SA is a Swiss-based speciality biopharmaceutical company dedicated to the development and commercialization of innovative drugs for women’s reproductive medicine. PregLem is a member of the Richter Group.
Completed Ph III
EMA approval as a pre-operative treatment of moderate to severe symptoms of uterine fibroids received in February 2012
(Steroid Sulfatase Inhibitor, STS-I)
Mild or Moderate Endometriosis: Phase IIa
(c-Jun-N-Terminal Kinase Inhibitor (JNK-I), Bentamapimod)
Inflammatory Endometriosis: Phase IIa / Proof of Concept (POC)
Adhesions: Phase IIa/Proof of Concept (POC)
(Somatostatin Antagonist, SST-ATG)
Ovarian Reserve Modulation: Pre-clinical development
European Commission approves Esmya® Type II variation, allowing a repeated course of 3-month treatment for uterine fibroids
Gedeon Richter Plc. (“Richter”) announces that Esmya® 5 mg tablets (ulipristal acetate) is now licensed for up to 2 intermittent courses of 3-month treatment for uterine fibroids in the European Union.